- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 35/00 - Antineoplastic agents
Patent holdings for IPC class A61P 35/00
Total number of patents in this class: 108829
10-year publication summary
|
2456
|
4431
|
6314
|
6708
|
7829
|
9089
|
9809
|
9903
|
9055
|
1327
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Novartis AG | 10463 |
984 |
| The Regents of the University of California | 20410 |
923 |
| Genentech, Inc. | 4045 |
769 |
| F. Hoffmann-La Roche AG | 7878 |
749 |
| Bristol-myers Squibb Company | 4795 |
712 |
| Dana-Farber Cancer Institute, Inc. | 2637 |
688 |
| Board of Regents, The University of Texas System | 6015 |
614 |
| Memorial Sloan-Kettering Cancer Center | 1992 |
518 |
| AstraZeneca AB | 2828 |
501 |
| The Johns Hopkins University | 5777 |
489 |
| Hoffmann-La Roche Inc. | 3620 |
480 |
| Merck Patent GmbH | 5729 |
474 |
| Centre National de La Recherche Scientifique | 10812 |
466 |
| Amgen Inc. | 4304 |
451 |
| Incyte Corporation | 1040 |
450 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2947 |
437 |
| Janssen Pharmaceutica N.V. | 3304 |
402 |
| Pfizer Inc. | 3373 |
401 |
| Institut National de La Sante et de La Recherche Medicale (inserm) | 3091 |
400 |
| Inserm (institut National de La Sante et de La Recherche Medicale) | 3354 |
399 |
| Other owners | 97522 |